US RE50,240 E1
Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
Hiroyuki Sonoda, Kobe (JP); and Kenichi Takahashi, Kobe (JP)
Assigned to JCR Pharmaceuticals Co., Ltd., Hyogo (JP)
Appl. No. 17/161,718
Filed by JCR Pharmaceuticals Co., Ltd., Hyogo (JP)
PCT Filed Dec. 26, 2017, PCT No. PCT/JP2017/046762
§ 371(c)(1), (2) Date Jun. 25, 2019,
PCT Pub. No. WO2018/124121, PCT Pub. Date Jul. 5, 2018.
Application 17/161,718 is a reissue of application No. 16/473,446, filed on Dec. 26, 2017, granted, now 10,759,864, issued on Sep. 1, 2020.
Claims priority of application No. 2016-252148 (JP), filed on Dec. 26, 2016.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 16/46 (2006.01); C12N 9/16 (2006.01); C12N 15/62 (2006.01)
CPC C07K 16/2881 (2013.01) [A61K 47/6809 (2017.08); A61K 47/6813 (2017.08); A61K 47/6815 (2017.08); C07K 16/2806 (2013.01); C07K 16/46 (2013.01); C12N 9/16 (2013.01); C12N 15/62 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)] 26 Claims
 
1. An anti-human transferrin receptor antibody, wherein in the heavy chain variable region of the antibody,
(a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63,
(b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and
(c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and
in the light chain variable region of the antibody,
(a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 6 or SEQ ID NO: 7,
(b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 8 or SEQ ID NO: 9, or the amino acid sequence Lys-Val-Ser, and
(c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 10 [ , and
framework region 3 of the heavy chain comprises the amino acid sequence set forth as SEQ ID NO: 64,
wherein the antibody is Fab antibody, F(ab′)2 antibody, or F(ab′) antibody] .